Sirio Pharma (300791) — Cash Flow-to-Debt Ratio
Sirio Pharma (300791) has a Cash Flow-to-Debt Ratio of 0.05x as of June 2023, meaning its operating cash flow of CN¥101.61 Million could theoretically repay 0% of its total liabilities (CN¥1.85 Billion) in one year. See financial agility of Sirio Pharma to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sirio Pharma Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Sirio Pharma across 9 annual periods. For the full cash flow conversion analysis, see 300791 cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sirio Pharma (2016–2024)
Year-by-year debt coverage analysis for Sirio Pharma. Check 300791 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.20x | CN¥566.97 Million | CN¥2.84 Billion | ▲ +35.7% |
| 2023 | 0.15x | CN¥386.08 Million | CN¥2.63 Billion | ▼ -51.0% |
| 2022 | 0.30x | CN¥444.86 Million | CN¥1.48 Billion | ▲ +12.0% |
| 2021 | 0.27x | CN¥341.38 Million | CN¥1.28 Billion | ▼ -60.9% |
| 2020 | 0.68x | CN¥319.57 Million | CN¥466.95 Million | ▲ +22.3% |
| 2019 | 0.56x | CN¥231.60 Million | CN¥414.01 Million | ▲ +131.6% |
| 2018 | 0.24x | CN¥183.46 Million | CN¥759.53 Million | ▲ +246.3% |
| 2017 | 0.07x | CN¥49.35 Million | CN¥707.58 Million | ▲ +170.8% |
| 2016 | -0.10x | CN¥-98.26 Million | CN¥997.00 Million | — |